Filing Details

Accession Number:
0001209191-17-002806
Form Type:
4
Zero Holdings:
No
Publication Time:
2017-01-06 21:35:19
Reporting Period:
2017-01-04
Filing Date:
2017-01-06
Accepted Time:
2017-01-06 21:35:19
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1437786 Immune Design Corp. IMDZ Pharmaceutical Preparations (2834) 262007174
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1605922 Wayne Gombotz C/O Immune Design Corp.
1616 Eastlake Ave. E., Suite 310
Seattle WA 98102
Chief Development Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2017-01-04 12,000 $0.00 24,034 No 4 A Direct
Common Stock Disposition 2017-01-04 980 $5.35 23,054 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 A Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Acquisiton 2017-01-04 70,000 $0.00 70,000 $5.60
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
70,000 2027-01-04 No 4 A Direct
Footnotes
  1. Each restricted stock unit represents a contingent right to receive one share of Immune Design Corp. common stock.
  2. One quarter of the total restricted stock units vest annually beginning January 4, 2018, subject to the Reporting Person's continuous service through each such date.
  3. The shares were sold pursuant to a Rule 10b5-1 trading plan that was included in the Reporting Person's restricted stock unit agreement, dated January 4, 2016, in order to satisfy a tax liability incurred upon the vesting of restricted stock units on January 4, 2017.
  4. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.25 to $5.42 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  5. One quarter of the shares underlying the option will vest on January 4, 2018, and the remainder of the shares underlying the option will vest at a rate of 1/36th per month thereafter, subject to the Reporting Person's continuous service through each such date.